NCI-H358 xenograft model

JH Jordan F Hastings
AR Alvaro Gonzalez Rajal
SL Sharissa L Latham
JH Jeremy ZR Han
RM Rachael A McCloy
YO Yolande EI O'Donnell
MP Monica Phimmachanh
AM Alexander D Murphy
AN Adnan Nagrial
DD Dariush Daneshvar
VC Venessa Chin
DW D Neil Watkins
AB Andrew Burgess
DC David R Croucher
request Request a Protocol
ask Ask a question
Favorite

NCI-H358 cells (2 × 106) resuspended in 100 μL PBS:Matrigel were injected subcutaneously into the flanks of nude mice. Tumour growth was assessed twice weekly by calliper measurement and mice were randomized to treatment arms when tumours reached 150 mm3 (using the formula: width2 x length x 0.5). Carboplatin (60 mg/kg) was delivered by a single tail-vein injection. Dactolisib was prepared in 10% DMSO:90% PEG300 and administered twice-weekly at 45 mg/kg by oral gavage. All in vivo experiments, procedures and endpoints were approved by the Garvan Institute of Medical Research Animal Ethics Committee.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A